Quantum BioPharma (NASDAQ: QNTM) disclosed the results of its November 10, 2026, annual general and special meeting of shareholders and the closing of a non-brokered private placement of 26 Class A multiple voting shares on November 9. The dual announcements, reported via NEWMEDIAWIRE, signal a deliberate tightening of insider control at the biopharmaceutical company as it advances its drug development pipeline.
At the meeting, shareholders elected all five director nominees, reappointed MNP LLP as auditor, and approved several resolutions. These included authorization to issue additional Class A multiple voting shares to maintain up to 70% aggregate voting power, a 2026 omnibus equity incentive plan, a potential share consolidation at a ratio of up to 10-for-1, and a potential corporate name change. The board retains discretion over whether and when to implement these authorized measures.
The private placement involved the issuance of 26 Class A multiple voting shares at C$3.11 per share, generating gross proceeds of C$80.86. Xorax Family Trust, associated with CEO Zeeshan Saeed, and Fortius Research and Trading Corp., controlled by director Anthony Durkacz, each acquired 13 shares. Following the placement, the aggregate voting power of Class A multiple voting shares increased from approximately 57.01% to 68.22%. The transaction was completed under shareholder authorization granted in 2025, with proceeds designated for general working capital purposes.
The increase in insider voting control is significant because it gives management and affiliated directors greater influence over corporate decisions, including the authorized share consolidation and name change. While the absolute dollar amount raised is minimal, the move aligns with the company’s stated goal of maintaining up to 70% aggregate voting power, ensuring that insiders can steer strategic direction without proportional economic dilution. For investors, this concentration of voting power may raise governance considerations, particularly regarding minority shareholder influence.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company focuses on its lead compound, Lucid-MS, a patented new chemical entity shown in preclinical models to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. Quantum also invented UNBUZZD(TM) and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake as of March 31, 2026, plus royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity.
The full press release is available at https://ibn.fm/UagXR, and additional details on Quantum BioPharma can be found through its Quantum BioPharma (NASDAQ: QNTM) profile. The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.


